Leerink analyst David Risinger lowered the firm’s price target on Xoma (XOMA) to $45 from $58 and keeps an Outperform rating on the shares. The firm removed RZ358 royal contributions from the company’s model after Xoma’s partner Rezolute (RZLT) announced a Phase 3 study failure. It believes RZ358’s growth prospects are still “robust” despite the failure in congenital hyperinsulinism.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA: